Aster DM Quality Care Q1: PAT crashes on ₹114cr merger cost; EBITDA still +27.5% YoY

Aster DM Quality Care (formerly Aster DM Healthcare) reported consolidated revenue of ₹1,310.7 Cr for Q1 FY27, up 21.6% YoY and 10.9% QoQ, on 16% YoY patient-volume growth — mature hospitals grew revenue 19% YoY while emerging hospitals grew 95% YoY. The profit line tells two stories depending on which figure is read: profit attributable to owners (the widely-reported number) fell 81.2% YoY to ₹16.1 Cr from ₹85.5 Cr, while total group profit for the period (including non-controlling interests, the basis comparable to our own quarter tracking) fell 68.7% YoY to ₹29.3 Cr from ₹93.6 Cr, and 80.9% QoQ from ₹153.6 Cr. Both declines trace to a single ₹114.4 Cr exceptional charge for merger-related professional fees, of which ₹109.8 Cr sat at the standalone entity, tipping standalone into an outright net loss of ₹14.3 Cr (from a ₹80.6 Cr profit a year ago) even as the consolidated group, with a larger earnings base, stayed marginally profitable.

Strip out the one-off and the underlying business looks considerably stronger than the headline suggests: EBITDA rose 27.5% YoY to ₹264.3 Cr, with margin expanding to 20.2% from 19.2% a year ago and ~19.7% last quarter — operating leverage from volume and case-mix growth is visibly showing up, as management had guided. Adjusted for the pretax exceptional item on both sides, PAT was approximately ₹143.7 Cr, up roughly 47% YoY — well ahead of the 21.6% revenue growth, which is the actual underlying story of the quarter. Working against that adjusted number was an effective tax rate that spiked to ~62.5% versus ~31.4% a year ago and just ~6% last quarter, likely reflecting non-deductibility of the merger costs, meaning even the adjusted profit growth understates the improvement in the operating line.

The stock went into the print at ₹842.1, up 6.7% over the past month of trading.

For context: revenue is at a 6-quarter high.

Against the pre-result preview, which specifically flagged "EBITDA margin and one-time costs" as a watch item, this quarter delivered close to that script: revenue at/slightly above the previewed ₹1,200-1,300 Cr range, and the 20.2% EBITDA margin within the previewed 20-22% band, while the one-time merger costs materialized as flagged and were the entire reason the reported bottom line missed. Management's prior guidance (Q4 FY26 call) had projected "continued strong revenue growth and margin expansion" and flagged the QCIL merger "expected to close in the current quarter" — both were met: revenue and margin expanded, and the Scheme was NCLT-sanctioned 19 June 2026, becoming effective 1 July 2026, one day after this quarter's close. That timing matters: this filing is still the legacy, pre-merger entity — none of Quality Care India Limited's hospitals (the CARE, Evercare and KIMS Health brands now on the letterhead) are in the consolidated entity list yet. Management has already disclosed a combined-proforma view: on a post-merger basis, revenue would be ₹2,597 Cr (+20% YoY) with operating EBITDA of ₹576 Cr (+30% YoY) at a 22.2% margin (+170bps) — the scale to expect once Q2 FY27 becomes the first quarter to actually consolidate QCIL. Elsewhere, the company completed its rebrand to Aster DM Quality Care Limited, PE investor BCP Asia II Topco IV acquired a 28.11% stake, and promoter holding was diluted to 24.01% — all mechanics of the same merger. MD & Group CEO Varun Khanna called the merger "a significant milestone," with commentary focused on integration and strengthening care delivery across the expanded network, consistent with the preview's "integration execution" framing.